<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03650205</url>
  </required_header>
  <id_info>
    <org_study_id>42559415520020065</org_study_id>
    <nct_id>NCT03650205</nct_id>
  </id_info>
  <brief_title>Ivabradine to Prevent Anthracycline-induced Cardiotoxicity</brief_title>
  <acronym>IPAC</acronym>
  <official_title>Ivabradine to Prevent Anthracycline-induced Cardiotoxicity: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anthracyclines are associated with cardiotoxic effects. Previous studies suggest that
      enalapril, and or carvedilol, protect against cardiovascular effects of these drugs.

      Ivabradine selectively reduces heart rate through inhibition of the cardiac pace maker IF
      channel, thus prolonging the duration of spontaneous depolarization in the sinus node.
      Additionally, ivabradine might preserve myocardial perfusion without negative inotropic
      effect and probably maintain cardiac contractility despite the reduction of heart rate.

      Ivabradine has been shown to improve outcome in patients with heart failure and angina. The
      aim of this study is to evaluate whether ivabradine might prevent anthracycline-induced
      cardiotoxicity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventricular function</measure>
    <time_frame>365 days after randomization</time_frame>
    <description>Reduction in global longitudinal strain of at least 10% (GLS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of mortality or major cardiovascular outcomes</measure>
    <time_frame>365 days after randomization</time_frame>
    <description>Composite endpoint of mortality or major cardiovascular outcomes (defined as acute myocardial infarction, heart failure, inappropriate sinus tachycardia and arrhythmia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular dysfunction</measure>
    <time_frame>365 days after randomization</time_frame>
    <description>Incidence of left ventricular (LV) dysfunction defined as reduction of LV ejection fraction by 10%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of myocardial injury</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>Levels of NT-proBNP and high-sensitivity cardiac troponin T</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of myocardial injury</measure>
    <time_frame>180 days after randomization</time_frame>
    <description>Levels of NT-proBNP and high-sensitivity cardiac troponin T</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of myocardial injury</measure>
    <time_frame>365 days after randomization</time_frame>
    <description>Levels of NT-proBNP and high-sensitivity cardiac troponin T</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic dysfunction</measure>
    <time_frame>365 days after randomization</time_frame>
    <description>Assessment by echocardiography the incidence of diastolic dysfunction using the following parameters: peak E-wave velocity, peak A-wave velocity, mitral valve (MV) E/A ratio, MV deceleration time, pulsed-wave tissue doppler imaging e' velocity, Mitral E/e', left atrium maximum volume index, pulmonary vein(PV) systole(S) wave, PV diastole (D) wave, continuous wave (CW) doppler: tricuspid regurgitation, systolic jet velocity; Color M- mode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular function</measure>
    <time_frame>180 days after randomization</time_frame>
    <description>Reduction in global longitudinal strain of at least 10% (GLS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Composite endpoint of mortality or major cardiovascular outcomes</measure>
    <time_frame>yearly after randomization until 5 years</time_frame>
    <description>Composite endpoint of mortality or major cardiovascular outcomes (defined as acute myocardial infarction, heart failure, inappropriate sinus tachycardia and arrhythmia)</description>
  </other_outcome>
  <other_outcome>
    <measure>Left ventricular dysfunction</measure>
    <time_frame>180 days after randomization</time_frame>
    <description>Incidence of left ventricular (LV) dysfunction defined as reduction of LV</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of myocardial injury</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>Levels of NT-proBNP and high-sensitivity cardiac troponin T</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of myocardial injury</measure>
    <time_frame>180 days after randomization</time_frame>
    <description>Levels of NT-proBNP and high-sensitivity cardiac troponin T</description>
  </other_outcome>
  <other_outcome>
    <measure>Diastolic dysfunction</measure>
    <time_frame>180 days after randomization</time_frame>
    <description>Assessment by echocardiography the incidence of diastolic dysfunction using the following parameters: peak E-wave velocity, peak A-wave velocity, mitral valve (MV) E/A ratio, MV deceleration time, pulsed-wave tissue doppler imaging e' velocity, Mitral E/e', left atrium maximum volume index, pulmonary vein(PV) systole(S) wave, PV diastole (D) wave, continuous wave (CW) doppler: tricuspid regurgitation, systolic jet velocity; Color M- mode.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>180 days after randomization</time_frame>
    <description>bradycardia, hypertension, atrial fibrillation, luminous phenomena, syncope, hypotension, erythema, rash, diplopia, vertigo, urticaria</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>365 days after randomization</time_frame>
    <description>bradycardia, hypertension, atrial fibrillation, luminous phenomena, syncope, hypotension, erythema, rash, diplopia, vertigo, urticaria</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>180 days after randomization</time_frame>
    <description>Assessment of heart variability through 24-hour holter the following parameters: mRR - ms, SDNN - ms, SDANN - ms, SDNNi - ms, rMSSD-ms, NN50, pNN50.</description>
  </other_outcome>
  <other_outcome>
    <measure>Oxygen consumption (VO2)</measure>
    <time_frame>180 days after randomization</time_frame>
    <description>Measurement of VO2 by cardiopulmonary exercise test</description>
  </other_outcome>
  <other_outcome>
    <measure>Ventilatory equivalents for oxygen (VE/VO2) and for carbon dioxide (VE/VCO2)</measure>
    <time_frame>180 days after randomization</time_frame>
    <description>Measurement of ventilatory equivalents for oxygen (VE/VO2) and for carbon dioxide (VE/VCO2) by cardiopulmonary exercise test</description>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Dimensions</measure>
    <time_frame>yearly after randomization until 5 years</time_frame>
    <description>LV diastolic diameter, LV diastolic diameter, LV diastolic diameter</description>
  </other_outcome>
  <other_outcome>
    <measure>Left ventricular geometry and mass</measure>
    <time_frame>yearly after randomization until 5 years</time_frame>
    <description>LV mass, Septal thickness, Posterior wall thickness</description>
  </other_outcome>
  <other_outcome>
    <measure>Subgroup analyses regarding the primary outcome</measure>
    <time_frame>365 days after randomization</time_frame>
    <description>Type of cancer, gender, age</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Neoplasms</condition>
  <condition>Heart Failure</condition>
  <condition>Cardiotoxicity</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>Oncology</condition>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive ivabradine just before anthracycline chemotherapy, 5 mg per oral twice daily, until one month after the last chemotherapy session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo just before anthracycline chemotherapy, one capsule per oral twice daily, until one month after the last chemotherapy session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>Ivabradine capsule</description>
    <arm_group_label>Ivabradine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral capsule.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo oral capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-year-old or older;

          -  Cancer diagnosis;

          -  Chemotherapy with anthracycline;

          -  Written informed consent

        Exclusion Criteria:

          -  Chronic Kidney Disease (Creatinine clearance inferior to 30mL/min/1.73m2)

          -  Bradycardia (heart rate less than 60 beats per minute)

          -  Atrial fibrilation;

          -  Previous diagnosis of heart failure;

          -  Pregnancy;

          -  History of previous hypersensibility to the study drug;

          -  Participating in another study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephanie I Rizk, MD</last_name>
    <phone>+551138932000</phone>
    <phone_ext>3271</phone_ext>
    <email>stephrizk@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ludhmila A Hajjar, MD, PhD</last_name>
    <phone>+551138932000</phone>
    <phone_ext>3272</phone_ext>
    <email>ludhmila@terra.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01246000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie I Rizk, MD</last_name>
      <phone>+551138933267</phone>
      <email>stephrizk@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ludhmila A Hajar, MD, PhD</last_name>
      <phone>+551138933267</phone>
      <email>ludhmila@terra.com.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>April 1, 2019</last_update_submitted>
  <last_update_submitted_qc>April 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Ludhmila Abrah√£o Hajjar</investigator_full_name>
    <investigator_title>Clinical director of the Instituto do Coracao, Faculdade de Medicina</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

